Teneligliptin mitigates diabetic cardiomyopathy through inflammasome inhibition:Insights from experimental studies  

作　　者：Chun-Yao Cheng Wen-Rui Hao Ju-Chi Liu Tzu-Hurng Cheng 

机构地区：[1]Department of Medical Education,National Taiwan University Hospital,Taipei 100225,Taiwan,China [2]Division of Cardiology,Department of Internal Medicine,Shuang Ho Hospital,Ministry of Health and Welfare,Taipei Medical University,New Taipei City 23561,Taiwan,China [3]Division of Cardiology,Department of Internal Medicine,School of Medicine,College of Medicine,Taipei Medical University,Taipei City 11002,Taiwan,China [4]Department of Biochemistry,School of Medicine,College of Medicine,China Medical University,Taichung City 404333,Taiwan,China

出　　处：《World Journal of Diabetes》2024年第12期2370-2375,共6页世界糖尿病杂志（英文）

摘　　要：This article provides commentary on the article by Zhang et al.In this original research,Zhang et al investigated the therapeutic potential of teneligliptin for diabetic cardiomyopathy(DCM),which was mediated by targeting the NOD-like receptor protein 3(NLRP3)inflammasome.Through the use of both in vivo and in vitro models,the study demonstrated that teneligliptin alleviates cardiac hyper-trophy,reduces myocardial injury,and mitigates the inflammatory responses as-sociated with DCM.These findings suggest that teneligliptin’s cardioprotective effects are mediated through the inhibition of NLRP3 inflammasome activation,positioning it as a promising therapeutic option for managing DCM in diabetic patients.

关 键 词：Diabetic cardiomyopathy Teneligliptin Nucleotide-binding oligomerization domain-like receptor 3 inflammasome Inflammasome inhibition 

分 类 号：R587.2[医药卫生—内分泌] R542.2[医药卫生—内科学]